Cargando…
Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients
The survival time of patients with early clear cell renal cell carcinoma (ccRCC) is fairly long, but 20% to 30% of patients with localized tumors experience relapse, and the effect of IFN-α on survival has not been well studied in patients with early ccRCC. In this study, 208 patients with early ccR...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762582/ https://www.ncbi.nlm.nih.gov/pubmed/29348897 http://dx.doi.org/10.18632/oncotarget.18567 |
_version_ | 1783291715507978240 |
---|---|
author | Yin, Hang Liao, Cheng-Gong Huang, Jian-Guo Wang, Yong-Qiang Li, Zheng Fan, Lu-Lu Qian, Men-Long Wan, Nao Lu, Ning |
author_facet | Yin, Hang Liao, Cheng-Gong Huang, Jian-Guo Wang, Yong-Qiang Li, Zheng Fan, Lu-Lu Qian, Men-Long Wan, Nao Lu, Ning |
author_sort | Yin, Hang |
collection | PubMed |
description | The survival time of patients with early clear cell renal cell carcinoma (ccRCC) is fairly long, but 20% to 30% of patients with localized tumors experience relapse, and the effect of IFN-α on survival has not been well studied in patients with early ccRCC. In this study, 208 patients with early ccRCC were treated with surgery, and 54 of the patients received IFN-α as adjuvant therapy. The remaining 115 patients were treated with surgery but not with IFN-α therapy. The primary endpoint was the recurrence rate, 20.37% (11/54) and 33.04% (38/115) in the IFN-α and surgery-only group, respectively. The secondary endpoint was progression-free survival (PFS), which was 123.70 (95% CI: 107.18–140.22) months for the IFN-α group, and 95.80 (95% CI: 82.18–109.42) months for the non-IFN-α group; this difference was significant (P < 0.05). The main side effects were pyrexia (61.11%), muscle pain (24.07%), malaise (9.26%), anorexia (5.56%), hepatic dysfunction (3.70%) and renal dysfunction (1.85%). Moreover, a multivariate regression identified older age, higher BMI index and smoking as significant and independent predictors of decreased PFS (P < 0.05). Overall, IFN-α therapy significantly improved PFS in Chinese patients with early ccRCC and was an independent prognostic factor (P < 0.05). In conclusion, our study showed that adjuvant IFN-α therapy decreased the recurrence rate and prolonged PFS in patients with ccRCC. Thus, this treatment may help clinicians to select a better treatment modality and better predict survival in these patients. |
format | Online Article Text |
id | pubmed-5762582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57625822018-01-18 Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients Yin, Hang Liao, Cheng-Gong Huang, Jian-Guo Wang, Yong-Qiang Li, Zheng Fan, Lu-Lu Qian, Men-Long Wan, Nao Lu, Ning Oncotarget Clinical Research Paper The survival time of patients with early clear cell renal cell carcinoma (ccRCC) is fairly long, but 20% to 30% of patients with localized tumors experience relapse, and the effect of IFN-α on survival has not been well studied in patients with early ccRCC. In this study, 208 patients with early ccRCC were treated with surgery, and 54 of the patients received IFN-α as adjuvant therapy. The remaining 115 patients were treated with surgery but not with IFN-α therapy. The primary endpoint was the recurrence rate, 20.37% (11/54) and 33.04% (38/115) in the IFN-α and surgery-only group, respectively. The secondary endpoint was progression-free survival (PFS), which was 123.70 (95% CI: 107.18–140.22) months for the IFN-α group, and 95.80 (95% CI: 82.18–109.42) months for the non-IFN-α group; this difference was significant (P < 0.05). The main side effects were pyrexia (61.11%), muscle pain (24.07%), malaise (9.26%), anorexia (5.56%), hepatic dysfunction (3.70%) and renal dysfunction (1.85%). Moreover, a multivariate regression identified older age, higher BMI index and smoking as significant and independent predictors of decreased PFS (P < 0.05). Overall, IFN-α therapy significantly improved PFS in Chinese patients with early ccRCC and was an independent prognostic factor (P < 0.05). In conclusion, our study showed that adjuvant IFN-α therapy decreased the recurrence rate and prolonged PFS in patients with ccRCC. Thus, this treatment may help clinicians to select a better treatment modality and better predict survival in these patients. Impact Journals LLC 2017-06-19 /pmc/articles/PMC5762582/ /pubmed/29348897 http://dx.doi.org/10.18632/oncotarget.18567 Text en Copyright: © 2017 Yin et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Clinical Research Paper Yin, Hang Liao, Cheng-Gong Huang, Jian-Guo Wang, Yong-Qiang Li, Zheng Fan, Lu-Lu Qian, Men-Long Wan, Nao Lu, Ning Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients |
title | Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients |
title_full | Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients |
title_fullStr | Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients |
title_full_unstemmed | Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients |
title_short | Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients |
title_sort | interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of chinese patients |
topic | Clinical Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762582/ https://www.ncbi.nlm.nih.gov/pubmed/29348897 http://dx.doi.org/10.18632/oncotarget.18567 |
work_keys_str_mv | AT yinhang interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients AT liaochenggong interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients AT huangjianguo interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients AT wangyongqiang interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients AT lizheng interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients AT fanlulu interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients AT qianmenlong interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients AT wannao interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients AT luning interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients |